Gara Jalqabaatti › Kansarii Ovarii › Missouri › St. Louis
Qorannoo klinikaalii Kansarii Ovarii St. Louis, MO keessatti
Qorannoo 38 Kansarii Ovarii f St. Louis fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
The Vanguard Study: Testing a New Way to Screen for Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Washington University School of Medicine, St Louis
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Washington University School of Medicine in St. Louis, St Louis
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Namoota walitti qabaa jiraSadarkaa 2/3
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Siteman Cancer Center at Christian Hospital, St Louis
- fi 2 dabalataa
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Namoota walitti qabaa jiraSadarkaa 2
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- Siteman Cancer Center-South County, St Louis
- fi 6 dabalataa
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University Medicine, St Louis
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine in St. Louis, St Louis
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- Washington University, School of Medicine, St Louis
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Namoota walitti qabaa jira
- WU St Louis, St Louis
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Washington University, St Louis
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Namoota walitti qabaa jiraSadarkaa 2
- Mercy David C. Pratt Cancer Center /ID# 275655, St Louis
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Namoota walitti qabaa jiraQorannoo ilaalaa
- Washington University, St Louis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine in St. Louis, St Louis
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Namoota walitti qabaa jiraSadarkaa 1/2
- Washington Univ. School of Medicine, St Louis
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Namoota walitti qabaa jiraSadarkaa 3
- Mercy Hospital St. Louis - David C. Pratt Cancer Center, St Louis
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Namoota walitti qabaa jiraSadarkaa 2
- Washington University, St Louis
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, St Louis
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Namoota walitti qabaa jiraSadarkaa 3
- Washington University School of Medicine ( Site 0052), St Louis
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Namoota walitti qabaa jiraSadarkaa 3
- Washington University School of Medicine, St Louis
- Mercy Hospital St. Louis, St Louis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Washington University School of Medicine, St Louis
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University, Siteman Cancer Center, St Louis
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Normunity Investigational Site, St Louis
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Namoota walitti qabaa jira
- Washington University School of Medicine, St Louis
- Missouri Baptist Medical Center, St Louis
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Mercy Infusion Center - Chippewa, St Louis
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- fi 5 dabalataa
IDOV-Immune for Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine, St Louis
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Washington University, St Louis
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Namoota walitti qabaa jiraSadarkaa 2/3
- Washington University School of Medicine Obstetrics and Gynecology, St Louis
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Investigative Site #110, St Louis
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Namoota walitti qabaa jiraSadarkaa 2
- 521, St Louis
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Washington University, St Louis
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Saint Louis University, St Louis
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Namoota walitti qabaa jiraSadarkaa 1/2
- Washington University, St Louis
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine in St. Louis, St Louis
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Namoota walitti qabaa jiraSadarkaa 1/2
- Research site, St Louis
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Washington University School of Medicine, St Louis
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Site 0111, St Louis
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Namoota walitti qabaa jira
- Washington University Medical Center, St Louis
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Namoota walitti qabaa jiraSadarkaa 2
- Washington University, St Louis
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, St Louis
Qorannoo Kansarii Ovarii magaalota biroo keessatti
- Houston, TXQorannoo 89
- New York City, NYQorannoo 69
- Boston, MAQorannoo 61
- Los Angeles, CAQorannoo 50
- Nashville, TNQorannoo 49
- Arlington, VAQorannoo 46
- Philadelphia, PAQorannoo 44
- Columbus, OHQorannoo 39
- Chicago, ILQorannoo 36
- San Antonio, TXQorannoo 31
- Cleveland, OHQorannoo 30
- Pittsburgh, PAQorannoo 30
Qorannoo biroo St. Louis keessatti
- Kansara Qara'a Non-Small CellQorannoo 73
- Saree OljooQorannoo 64
- Kansara MetastatikiiQorannoo 54
- Kansarii ColorectalQorannoo 50
- Saree (Gosoota Hunda)Qorannoo 46
- Kansarii ProstateQorannoo 46
- Dhibee QaraQorannoo 39
- Kansarii PancreasQorannoo 33
- Kansa EndometiriyaaliiQorannoo 29
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 28
- Cufama OnneeQorannoo 26
- ObesityQorannoo 25
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.